Evidence method
Level · gp.fundamentals.capex_revenue_ratio
4.83% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
ANIK · Mar 31, 2026
Anika Therapeutics, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001171843-26-002852General Corporate
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
-16.36% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.revenue
13.16% · CORE · VALID
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
77.12% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.gross_margin
64.15% · CORE · VALID
Evidence method
Level · gp.fundamentals.operating_margin
-18.53% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
22.67% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
22.43% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History15 statesHistory building
Dec 31, 20220/7 normalizedLevel 3Mar 31, 20230/7 normalizedLevel 3Jun 30, 20230/7 normalizedLevel 3Sep 30, 20230/7 normalizedLevel 3Dec 31, 20230/8 normalizedLevel 3Mar 31, 20240/8 normalizedLevel 3Jun 30, 20240/8 normalizedLevel 3Sep 30, 20240/8 normalizedLevel 3Dec 31, 20247/8 normalizedLevel 3Mar 31, 20257/8 normalizedLevel 3Jun 30, 20257/8 normalizedLevel 3Sep 30, 20256/7 normalizedLevel 3Dec 31, 20258/8 normalizedLevel 3Mar 31, 20268/8 normalizedLevel 3Jun 30, 20268/8 normalizedLevel 3
Period transition
What moved in the state?
- Previous
- 6.05%
- Current
- 4.83%
- Delta
- -1.22%
- Previous
- 9.92%
- Current
- -16.36%
- Delta
- -26.28%
- Previous
- -5.91%
- Current
- 13.16%
- Delta
- 19.07%
- Previous
- 16.65%
- Current
- 77.12%
- Delta
- 60.47%
- Previous
- 56.56%
- Current
- 64.15%
- Delta
- 7.60%
- Previous
- -9.80%
- Current
- -18.53%
- Delta
- -8.74%
- Previous
- 22.84%
- Current
- 22.67%
- Delta
- -0.17%
- Previous
- 8.94%
- Current
- 22.43%
- Delta
- 13.49%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Has State · Anika Therapeutics, Inc. →Transitioned To · ANIK Fundamental State →Transitioned To · ANIK CAPEX_INTENSITY_DECREASED →Transitioned To · ANIK CASH_GENERATION_DECREASED →Transitioned To · ANIK GROWTH_INCREASED →Transitioned To · ANIK INVENTORY_PRESSURE_INCREASED →Transitioned To · ANIK MARGIN_INCREASED →Transitioned To · ANIK PROFITABILITY_DECREASED →Transitioned To · ANIK R_AND_D_INTENSITY_DECREASED →Transitioned To · ANIK SBC_INTENSITY_INCREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.